(J Pharm Sci 2022, 2022: Formulation study reporting that ivermectin, co-loaded with the TLR7/8 agonist resiquimod in a squalene nanoemulsion, enhances immunogenic cell death and improves antitumour activity in vitro and in vivo.
In the present study, IVM was shown to enhance the ICD process in addition to the treatment of resiquimod (R848), a TLR7/8 agonist, when co-loaded in a squalene-based nanoemulsion (NE).
n/a (PubMed record)
(J Pharm Sci 2022, 2022: Formulation study reporting that ivermectin, co-loaded with the TLR7/8 agonist resiquimod in a squalene nanoemulsion, enhances immunogenic cell death and improves antitumour activity in vitro and in vivo. Study type: nanoparticle formulation, in vitro characterisation plus in vivo antitumour testing. N: not stated in the abstract. Country: not stated in the retrieved record (Elsevier journal). Dose: not stated in the abstract. Funder/COI: not stated in the PubMed record. Comparator: free drug and single-agent controls. The authors also state that 'a single treatment of IVM-free drug is not an ideal anticancer therapy due to its anti-inflammatory effects and cytotoxicity', a limiting remark recorded as written. Study type: animal.
